New Two-Drug attack on tough liver cancer
NCT ID NCT05174650
Summary
This study is testing whether combining two drugs, atezolizumab and derazantinib, can help control advanced bile duct cancer that has a specific genetic feature called an FGFR2 fusion. It is for adults who have had at most one prior treatment. The main goal is to see how many patients' tumors shrink in response to this combination therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexianer Krefeld GmbH
Krefeld, Germany
-
HELIOS KLinikum Bad Saarow
Bad Saarow, Germany
-
Johanniter Krankenhaus Bonn
Bonn, Germany
-
Klinikum Esslingen
Esslingen am Neckar, Germany
-
Klinikum rechts der Isar, Technische Universität München
München, Germany
-
Krankenhaus Nordwest gGmbH
Frankfurt, Germany
-
LMU München Großhadern
Munich, Germany
-
MVZ am Oskar-Helene Heim Berlin
Berlin, Germany
-
Marienhospital Wesel
Wesel, Germany
-
Medizinische Hochschule Hannover
Hanover, Germany
-
Uniklinikum Köln
Cologne, Germany
-
Universitätsklinikum Leipzig
Leipzig, Germany
-
Universitätsklinikum Tübingen
Tübingen, Germany
-
Universitätsmedizin Berlin Charité
Berlin, Germany
-
Universitätsmedizin Mainz
Mainz, Germany
-
Universitätsmedizin Mannheim
Mannheim, Germany
-
Vivantes Klinikum Berlin Friedrichshain
Berlin, Germany
Conditions
Explore the condition pages connected to this study.